Table 3 Correlation of topoisomerase isoenzymes with TP53 status of all EOC patients
From: Targeting of topoisomerases for prognosis and drug resistance in ovarian cancer
Topoisomerases | TP53 status | Case-low | Case-high | HR (% 95 CI) | P-value |
|---|---|---|---|---|---|
TOP1 | Mutated | 109 | 303 | 0.83 (0.63−1.09) | 0.18 |
|  | Wild type | 54 | 32 | 1.91 (1.04−3.49) | 0.033 |
TOP2A | Mutated | 278 | 161 | 1.32 (1.02−1.7) | 0.036 |
|  | Wild type | 30 | 56 | 0.74 (0.41−1.33) | 0.31 |
TOP2B | Mutated | 252 | 187 | 0.78 (0.6−1.02) | 0.066 |
|  | Wild type | 38 | 48 | 1.34 (0.73−2.46) | 0.34 |
TOP3A | Mutated | 300 | 139 | 1.17 (0.89−1.52) | 0.26 |
|  | Wild type | 63 | 23 | 0.68 (0.33−1.42) | 0.3 |
TOP3B | Mutated | 304 | 135 | 1.26 (0.97−1.64) | 0.086 |
|  | Wild type | 42 | 44 | 1.45 (0.81−2.62) | 0.21 |